Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.61 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18857083 | 0.91 | HTR2C (0.64) | HTR2CMTNR1AMTNR1BHTR2AHDAC3 | |
| SCHEMBL10413240 | 0.83 | MTNR1A (0.59) | HTR2CMTNR1AMTNR1BHTR2AHDAC3 | |
| SCHEMBL18856948 | 0.82 | MTNR1A (0.58) | HTR2CMTNR1AMTNR1BHTR2AHDAC3 | |
| SCHEMBL22930048 | 0.82 | HTR2C (0.59) | HTR2CHTR2APRMT5MAPT | |
| SCHEMBL14041592 | 0.82 | MTNR1A (0.58) | HTR2CMTNR1AMTNR1BHTR2AHDAC3 | |
| SCHEMBL19148280 | 0.82 | HTR2C (0.57) | HTR2CMTNR1AMTNR1BHTR2AHDAC3 | |
| SCHEMBL22930056 | 0.81 | HTR2C (0.77) | HTR2CMTNR1AMTNR1BHTR2AHDAC8 | |
| SCHEMBL8114271 | 0.81 | HTR2C (0.56) | HTR2CMTNR1AMTNR1BHTR2AHDAC3 | |
| SCHEMBL5841872 | 0.81 | HTR2C (0.55) | HTR2CMTNR1AMTNR1BHTR2AHDAC3 | |
| SCHEMBL4394621 | 0.81 | MTNR1A (0.56) | HTR2CMTNR1AMTNR1BHTR2AHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10905769-B2 | Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2021-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10905769-B2 | Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use | PLK1, POLR1E, POLK | HTR2C 4526/4885MTNR1A 2835/4885MTNR1B 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.